Bridge the gap from animal to human PK with a validated, expert-developed workflow – ready to activate directly in your Phoenix workspace.
Be Ready to Go in 2026: Unlock Translational PK Insights in Phoenix®
In today’s translational pharmacokinetics (PK) environment, teams spend up to 90% of their time simply preparing, cleaning, collating and validating data, time that should be spent on insight, interpretation and decision-making. When you’re trying to scale animal data to human predictions, build confidence in your first-in-human (FIH) dose or move smoothly toward your IND filing, you can’t afford to be bogged down in spreadsheets, siloed data and manual report generation. That’s where the latest workflow from Certara comes in: a validated, expert-developed translational PK model embedded in the Phoenix® PK/PD Platform environment, now enhanced with AI-driven automation of report generation, consistent data preparation and streamlined modeling and visualization.
By reducing analysis time and improving data consistency, you accelerate your early-development decision-making and gain the confidence to push toward your IND and FIH milestones with clarity and momentum.
Certara’s translational PK modeling workflow gives you the ability to translate animal data into human insights directly within Phoenix, combining modeling, simulation, and visualization in one unified workflow.
Validated by experts and built on published methodologies, this workflow helps you:
Efficiently scale PK data from animals to humans
Integrate all modeling and graphics within a single project view
Reduce analysis time and improve data consistency
Accelerate early development decision-making with greater confidence
Whether you’re building translational capabilities now or refining next year’s strategy, Certara experts can help you hit the ground running in 2026.
Enhance Strategic Impact Before Year-End
Pair the Translational PK Workflow with Certara’s Expert Development Advisory Board to gain targeted insights and validation from 250+ global specialists in clinical pharmacology, regulatory strategy, and translational science.
In just 2-3 weeks, our board can help you:
- Validate your PK approach and study design
- Identify the optimal translational strategy for your asset
- Deliver clear, actionable recommendations to advance your 2026 pipeline
Act now! Book your advisory review before December 15.
